EMA’s human medicines committee (CHMP) has recommended authorising the COVID-19 vaccine Bimervax (previously COVID-19 Vaccine HIPRA) as a booster in people aged 16 years and above who have been vaccinated with an mRNA COVID-19 vaccine.
Bimervax, developed by HIPRA, contains a protein produced in the laboratory that consists of part of the SARS-CoV-2 spike protein from the Alpha and Beta virus variants.
We would like to congratulate HIPRA and everyone else involved in the development of the vaccine!!!
At ASPHALION, we are deeply proud to have contributed to this achievement as Regulatory partners throughout the whole process.
You can check here for further information: